Key Takeaways Genmab shares jumped 21.9% in a month on plans to acquire Merus for $8 billion in cash.The acquisition adds petosemtamab, a late-stage oncology candidate, to GMAB's proprietary pipeline.GMAB expects petosemtamab to drive growth, with potential billion-dollar sales contributions by 2029.Shares of Genmab A/S (GMAB) have rallied 21.9% in a month. The stock price rally was observed after the company signed a definitive agreement in late September to acquire Merus N.V. (MRUS) for $97 per share in c ...

Group 1: Verint Systems Inc. - Verint Systems Inc. is under investigation related to its sale to Thoma Bravo, with shareholders set to receive $20.50 per share in cash [1] Group 2: Electronic Arts Inc. - Electronic Arts Inc. is involved in a sale to an investor consortium including PIF, Silver Lake, and Affinity Partners, with stockholders expected to receive $210.00 in cash per share [2] Group 3: Merus N.V. - Merus N.V. is being sold to GEnmad A/S, with stockholders to receive $97.00 in cash per share [3] Group 4: The Farmers Savings Bank - The Farmers Savings Bank is set to be sold to Civista Bancshares, Inc., where each common share will convert into $69,850 in cash and approximately 2,869 Civista common shares [4]

Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform. Source: Pixabay According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previou ...

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Electronic Arts Inc. (NASDAQ: EA)’s sale to an investor consortium comprised of PIF, Silver Lake, and Affinity Partners for $210.00 per share in cash. If you are an Electronic Arts shareholder, click here to learn more about your rights and options. Merus N.V ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Merus N.V. (NASDAQ: MRUS) related to its sale to GEnmad A/S. Under the terms of the propose ...

We recently published 10 Stocks With 10-60% Upside. Merus NV (NASDAQ:MRUS) is one of the top performers on Monday. Shares of Merus NV soared to a new record high on Monday, as investors gobbled up shares following news that it was set to be acquired by Genmab AS at a 41-percent premium. In a statement, Genmab AS said that it entered into an agreement with Merus NV (NASDAQ:MRUS) for the acquisition of the latter, through its subsidiary, Purchaser, for $8 billion. Merus (MRUS) Soars to New High on Genmab ...

Core Insights - Genmab has agreed to acquire all shares of Merus for $97 per share, totaling $8 billion, enhancing its oncology pipeline [1][4] - The acquisition is supported by both companies' boards and is expected to transition Genmab to a fully owned business model [1][2] - The deal is projected to close in early Q1 2026, with a key asset being Merus' petosemtamab, currently in Phase III development [2][3] Financial Details - The acquisition price represents a 41% premium over Merus' closing stock price on September 26, 2025, and a 44% premium over the 30-day volume-weighted average price of $67.42 [4] - Genmab plans to finance the acquisition through existing cash and $5.5 billion in non-convertible debt, with backing from Morgan Stanley Senior Funding [4] Strategic Implications - The acquisition aligns with Genmab's long-term strategy to become a global biotechnology leader, providing sustainable growth into the next decade [6] - Petosemtamab is expected to be a transformative therapy for head and neck cancer, with potential launch in 2027 depending on clinical outcomes and regulatory approvals [3][6] Advisory Information - Genmab is advised by PJT Partners and Morgan Stanley & Co International, with legal counsel from A&O Shearman and Kromann Reumert [5] - Merus is advised by Jefferies, with legal counsel from Latham & Watkins and NautaDutilh [5]

此次要约收购中支付的每股普通股 97.00 美元的收购价格较 Merus 2025 年 9 月 26 日的收盘价 68.89 美 元溢价约 41%，较 Merus 30 天成交量加权平均价 67.42 美元溢价约 44%。 来源：市场资讯 （来源：求实药社） 当地时间 9 月 29 日，Genmab A/S 和 Merus NV 今日宣布，双方已达成交易协议。根据协议，Genmab 拟以每股 97.00 美元的价格全现金收购 Merus 的全部股份。此次收购将以现金方式进行，交易价值约为 80 亿美元。 该交易已获得两家公司董事会的一致批准。Genmab 的全资子公司将对 Merus 100% 的普通股发起要约 收购，预计将于 2026 年第一季度初完成。 | 0 = 00 | CARD STORE FOR CONSULTION CONSULTION CONSULTION OF CONSULTION OF | | --- | --- | | [ Global M Genmab | Nealthcare Professionals Patterco & Care Partnerships Contact AND ...

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]

Core Insights - Genmab A/S is acquiring Merus N.V. for $97 per share in an all-cash transaction valued at approximately $8 billion, aimed at enhancing its oncology portfolio [1][6] - The acquisition includes Merus' late-stage asset, petosemtamab, which is in Phase 3 development, expected to accelerate Genmab's transition to a wholly owned model [3][6] - Following the acquisition, Genmab will have four proprietary programs ready to drive multiple new drug launches, diversifying its revenue streams [4] Financial Metrics - Leerink Partners has set a price target of $34 for GMAB, indicating a potential increase of about 16.61% from its current trading price of $29.33 [2][6] - Genmab's market capitalization is approximately $18.51 billion, with a trading volume of 5.03 million shares on NASDAQ [4] - Merus' stock surged by 38% following the acquisition announcement, reflecting a positive market response [5] Strategic Implications - The acquisition is a significant step for Genmab in expanding its capabilities in cancer treatment and is expected to support sustained growth into the next decade [3][5] - The deal is anticipated to close by early in the first quarter of 2026, aligning with Genmab's strategic goals [3]